Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Madrigal Pharmaceuticals, Inc. MDGL NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
54/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$705.67
+36.1%

Balance sheet is a point-in-time snapshot. TTM shows the most recent available quarter.

Metric Latest Quarter (2025-12)
Total Assets $1.26B
Total Liabilities $656.9M
Total Debt $354.36M
Cash & Investments $983.56M
Total Stockholders Equity $602.69M

People Also View

KRYS
KRYS
Krystal Biotech, Inc.
$268.54
-0.54%
 ACLX
ACLX
Arcellx, Inc.
$115.00
+0.10%
 PTCT
PTCT
PTC Therapeutics, Inc.
$73.57
+0.77%
 TGTX
TGTX
TG Therapeutics, Inc.
$34.60
+0.12%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 VKTX
VKTX
Viking Therapeutics, Inc.
$35.45
-0.20%
 SRPT
SRPT
Sarepta Therapeutics, Inc.
$21.73
-1.90%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.47
+0.05%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message